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The CA125 tumour marker has an established clinical role in
monitoring the course of ovarian cancer during and after therapy
(Rustin et al, 1996a, 1996b). In addition this marker is of value as
a prognostic indicator (Gadducci et al, 1995; Nagele et al, 1995)
and in the differential diagnosis of pelvic adnexal masses in
symptomatic patients (Jacobs et al, 1990; Tingulstad et al, 1996).
CA125 is also currently under investigation as a potential
screening test for ovarian cancer (Jacobs et al, 1993). Although the
role of CA125 in screening remains controversial, there is
evidence that serum elevation is associated with an increased risk
of ovarian cancer. We have previously reported that asymptomatic
postmenopausal women with a CA125 ³ 30 U ml–1 have a 36-fold
increased risk of diagnosis for ovarian cancer in the subsequent
year (Jacobs et al, 1996). This data was derived from a multimodal
screening study which used pelvic ultrasound as a secondary test.
We have now been able to perform a further analysis to quantify
the value of pelvic ultrasound in refining the risk of cancer
amongst asymptomatic women with CA125 elevation.
METHODS
Design
The overall study design has been described in a previous report
(Jacobs et al, 1988, 1993). A total of 22 000 post-menopausal
women, aged ³ 45 years underwent serum CA125 screening.
Women with a CA125 level ³ 30 U ml–1 underwent an ultrasound.
Transabdominal and/or transvaginal ultrasonography was used to
measure the diameter of each ovary in three planes and to docu-
ment ovarian morphology. Ovarian volume was calculated using
the formula for an ovoid (Campbell et al, 1989). Ovarian
morphology was classified as normal if the ovaries exhibited
uniform hypoechogenicity and smooth outlines. All other morpho-
logical appearances were classified as abnormal. Women with
abnormal results on scan were referred to a gynaecologist for
assessment and further management. All women were followed up
annually during the study by a questionnaire that specifically
enquired about any illness or hospital visit in the previous year.
When information suggested that a study participant may have had
a gynaecological malignancy, histopathological and clinical infor-
mation was obtained from the general practitioner and/or hospital.
Statistical analysis
Index cancers were defined as primary invasive epithelial carci-
nomas of the ovary and fallopian tube (Jacobs et al, 1996). The
risk of index cancer at time interval t from the date of ultrasound in
volunteers with scans satisfying a particular ultrasound criterion
(abnormal ovarian morphology and volume over a specified cut-
off) was calculated by dividing the number of volunteers with
scans satisfying that criterion who developed index cancers within
time t by the total number of volunteers with scans satisfying the
criterion. Cumulative risk curves were constructed by plotting the
calculated risk values against time. The observed risk of index
cancer for all 22 000 study volunteers as well as for all volunteers
with CA125 ³ 30 U ml–1 at a given time interval t had been previ-
ously calculated (Jacobs et al, 1996). The relative risks of cancer at
1 and 5 years were computed by dividing the calculated risk for
women satisfying a specified ultrasound criterion at 1 and 5 years
by the observed risk for the entire study population at 1 and 5 years
respectively. Confidence intervals (CI) for the risk estimates and
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the relative risk (RR) estimates were calculated using the Taylor
series method (Rothman, 1986).
RESULTS
Of the 22 000 study participants, 741 had a CA125 ³ 30 U ml–1
and underwent a scan. A further 26 volunteers with a CA125
³ 30 U ml–1 declined an ultrasound (n = 15) or were found to be
premenopausal (n = 11) and were therefore not included in the
analysis. Twenty index cancers were diagnosed amongst the 741
women with a CA125 ³ 30 U ml–1 during a median follow-up of
6.8 years. The index cancers were invasive epithelial cancers of
the following histological types; serous (seven), endometroid
(six), clear cell (two), undifferentiated (one) and fallopian tube
Table 1 Relative risk of index cancer at 1 and 5 years follow-up for various ovarian ultrasound criteria
Criteria USS Relative riska Relative risk Serum CA125
1 year 5 years (U/ml)
Median (range)
Entire populationb 11
CA125 < 30 U ml–1 b 0.13 0.54
(0.03–0.58) (0.32–0.91)
CA125 ³ 30 U ml–1 b 36 14.3
(18–70) (8.5–24)
CA125 ³ 30 U ml–1 Normal c 0.76 35.6
morphology (0.09–5.96) (30–318)
Abnormal 327 119 39.2
morphology (150–708) (56–244) (30–>500)
Abnormal 503 183 39.9
morphology and (218–1164) (83–402) (30–>500)
volume ³ 20 ml
Abnormal 617 224 40.6
morphology and (254–1495) (97–518) (30–134)
volume ³ 50 ml
Abnormal 809 294 40.6
morphology and (302–2171) (114–756) (30–108)
volume > 100 ml
a95% confidence limits shown in parenthesis. bPreviously published (Jacobs et al, 1996). cThe figure could not be
calculated because no index cancers occurred in this group until 2.3 years of follow-up
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Figure 1 Cumulative risk of developing an index cancer according to CA125 and ultrasound in asymptomatic post-menopausal women. (A) Entire study
population of 22 000 women; (B) all women with a CA125 ³ 30 U ml–1; (C) CA125 ³ 30 U ml–1 and normal ovarian morphology; (D) CA125 ³ 30 U ml–1 and
abnormal ovarian morphology; (E) CA125 ³ 30 U ml–1, abnormal morphology and ovarian volume ³ 20 ml; (F) CA125 ³ 30 U ml–1, abnormal ovarian morphology
and ovarian volume ³ 100 ml. The cumulative risk curves (A,B) for all women with CA125 ³ 30 U ml–1 and the entire study population, shown in dotted lines, are
reproduced from a previous analysis involving the same study population (Jacobs et al, 1996). Note that no index cancers developed in the women with a
CA125 ³ 30 U ml–1 and normal ovarian morphology on scan in the initial 2 years following the scan episode. As a result, this curve (C) commences at 2.3 years(three). The number of index cancers at FIGO (International
Federation of Gynaecology and Obstetrics) stages I, II, III and IV
were seven, one, nine and two respectively. The histological type
and precise stage were not known for one patient whose diagnosis
was on the basis of imaging findings, clinical assessment and an
ascitic tap which revealed adenocarcinoma cells.
A total of 662/741 women had normal ovarian morphology on
scan of whom only one had a subsequent diagnosis of an index
cancer (at 2.3 years of follow-up). Of the 79/741 women with
abnormal ovarian morphology, 19 had a subsequent diagnosis of
an index cancer. Of the women with abnormal morphology and an
ovarian volume ³ 20 ml and ³ 100 ml, 15/41 and 10/17, respec-
tively, had a subsequent diagnosis of an index cancer.
Figure 1 shows the relation between cumulative risk of devel-
oping an index cancer according to CA125 and ultrasound find-
ings. Compared to the entire study population (curve A), women
with a CA125 ³ 30 U ml–1 (curve B) had an increased risk of
developing an index cancer. However, the subgroup of women
with an elevated CA125 but normal ovarian morphology (curve C)
had a similar cumulative risk to the entire study population (Jacobs
et al, 1996) (0.15% vs 0.22%, 95% CI 0.02–1.12 vs 0.18–0.30). In
contrast, the cumulative risk of developing index cancer in women
with a CA125 ³ 30 U ml–1 and abnormal morphology (curve D)
was 24% (95% CI 15–38). Further stratification of risk assessment
was achieved by incorporating volume measurements in addition
to morphology. The cumulative risk for index cancer in women
with CA125 ³ 30 U ml–1 associated with abnormal morphology
and ovarian volume of ³ 20 ml (curve E) and ³ 100 ml (curve F)
was 37% (95% CI 22–61) and 59% (95% CI 32–111) respectively.
The RR of an index cancer at 1 and 5 years follow-up for
various criteria are shown in Table 1. Among volunteers with a
raised CA125 and abnormal ovarian morphology, the RR of index
cancer at 1 year was 327 compared to the entire study population
(RR 1.0). The highest RR at 1-year follow-up was for women with
a CA125 ³ 30 U ml–1 whose ultrasound revealed abnormal
morphology and ovarian volume ³ 100 ml (RR 809, 95% CI
302–2165). Further stratification of women with abnormal ovarian
morphology on the basis of CA125 level revealed that the 29 with
CA125 > 50 U ml–1 had a RR of 664 (95% CI 277–1590) and the
ten with a CA125 > 100 U ml–1 had a RR of 1682 (95% CI
486.5–5816).
DISCUSSION
We have previously reported that asymptomatic post-menopausal
women with a CA125 level ³ 30 U ml–1 have a 36-fold increased
risk of ovarian cancer compared to the general population (Jacobs
et al, 1996). This finding justified close surveillance of all post-
menopausal women undergoing ovarian cancer screening who
were found to have an elevated serum CA125. In the St
Bartholomew’s/Royal London Hospital Study this surveillance
was undertaken using pelvic ultrasonography. The incidence of
ovarian cancer on long-term follow-up and the details of ultra-
sound findings in the study were available for analysis. It was
therefore possible to assess the impact of ultrasound on ovarian
cancer risk stratification. The findings indicate that women at
increased risk on the basis of an elevated CA125 can be further
stratified for ovarian cancer risk according to ultrasound findings.
The majority (89%) of women with an elevated CA125 had
normal scan findings. None of these women developed an index
cancer within 1 year, and only 1/662 during the full duration of the
study follow-up. This group of women were not at increased risk
of an index cancer compared to the general population despite
their CA125 elevation. On the basis of this finding, women with
an elevated CA125 but normal ultrasound can be reassured about
their level of risk of ovarian cancer. The protocol for our ongoing
ovarian cancer screening trial reflects this data and women in this
group are not recalled for additional surveillance.
In contrast, women with a raised CA125 and abnormal ultra-
sound findings are at a markedly increased risk of an index cancer.
The risk of index cancer during the subsequent year for women
with a CA125 ³ 30 U ml–1 and abnormal ovarian morphology on
scan was 300-fold that of the entire population. This risk is signifi-
cantly higher than the risk associated with an elevated CA125 alone
(Jacobs et al, 1996). In view of the documentation of this high risk,
the combination of CA125 elevation and abnormal ovarian scan
findings justifies prompt investigation even when found in asymp-
tomatic women. Our current screening protocol requires immediate
referral for a specialist opinion for women in this category.
Further risk stratification was possible on the basis of ovarian
volume measurements at ultrasound. Asymptomatic post-meno-
pausal women with a CA125 ³ 30 U ml–1, abnormal ovarian
morphology and an ovarian volume ³ 100 ml were at 800-fold
increased risk of diagnosis of an index cancer during the subsequent
year. Risk stratification, according to the details of morphological
findings may be valuable but was not feasible within the size of our
dataset. Further analysis suggested that within the small group of
women with abnormal ovarian morphology, the risk of ovarian
cancer could be further categorized according to CA125 level.
The impact of screening for ovarian cancer on mortality is still
uncertain. Furthermore, screening has a well-documented false-
positive rate which can result in anxiety and morbidity associated
with surgical investigation. For these reasons ovarian cancer
screening should be limited to women at high risk because of a
strong family history and women participating in research trials.
Nevertheless, inappropriate screening is performed and clinicians
are increasingly faced with the problem of CA125 elevation in
asymptomatic women. The results of this analysis provide some
guidance for management of post-menopausal women in this situ-
ation and for the design of future research trials to assess the
impact of ovarian cancer screening. It is clear that ultrasound
can separate asymptomatic post-menopausal women with raised
CA125 levels into those who have normal scans and are not at
increased risk of ovarian cancer and those with abnormal scans
who are at substantially increased risk of ovarian cancer.
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